Solventum (SOLV) stock
Health Care · Health Care Technology
Solventum (SOLV) is a Health Care Technology company in the Health Care sector, headquartered in Saint Paul, Minnesota. As of October 23, 2026, SOLV closed at $85.41, a market capitalization of $14.54 billion, the 453rd largest company in the S&P 500. Over the last twelve months it generated $8.31 billion in revenue (+2% year over year) and -$118.00 million in free cash flow. The stock trades at 10.5x trailing earnings and 11.8x forward earnings.
- 1-year total return: +18.2% (dividends reinvested)
- 52-week range: $62.38 – $94.16
- Gross margin 54.8%, operating margin 9.8%
- FI Handbook report card: C- across 10 metrics
- 52nd largest of 60 Health Care stocks in the S&P 500
SOLV price chart
1Y price change: +18.2% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| SOLV | -3.3% | +7.8% | +18.2% | — | — | — | +2.6% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 2024.
SOLV key statistics
- Market cap
- $14.5B
- #453 in S&P 500
- P/E (TTM)
- 10.5x
- Forward P/E
- 11.8x
- EPS (TTM)
- $8.17
- Revenue (TTM)
- $8.3B
- +2%
- Free cash flow
- -$118.0M
- Gross margin
- 54.8%
- Operating margin
- 9.8%
- Return on equity
- 34.0%
- Dividend yield
- None
- 52-week range
- $62.38 – $94.16
- Beta
- 0.70
- Price / sales
- 1.7x
- EV / EBITDA
- 17.1x
- Debt / equity
- 1.10x
- Employees
- 20,584
SOLV report card
C-Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth2.2%D
- Gross margin54.8%B
- Operating margin9.8%D
- FCF margin-1.4%F
- Return on equity34.0%A
- Net debt / EBITDA4.3xF
- Forward P/E11.8xA
- PEG ratio1.2xB
- Shareholder yield0.0%F
- Share count change / yr0.5%C
Solventum financials
Revenue went from $8.1B in fiscal 2022 to $8.3B in fiscal 2025, growing 0.8% a year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $8.1B | $8.2B | $8.3B | $8.3B |
| Gross profit | $4.7B | $4.7B | $4.6B | $4.5B |
| Operating income | $1.7B | $1.7B | $1.0B | $2.2B |
| Net income | $1.3B | $1.3B | $479.0M | $1.6B |
| EPS (diluted) | $7.78 | $7.79 | $2.76 | $8.88 |
| Free cash flow | $1.4B | $1.6B | $805.0M | -$10.0M |
| Diluted shares | 172.7M | 172.7M | 173.7M | 175.3M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into SOLV?
A reverse DCF asks what growth the current price requires. With an enterprise value of $19.4B and -$118.0M of trailing free cash flow, Solventum needs to grow free cash flow at a rate outside our model for ten years (fading to 3.0% terminal growth) to earn a 10% annual return.
P/E ratio history
Current 9.6x vs. median 9.6x (10th–90th percentile 7.6x–27.5x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
SOLV analyst price targets
13 analysts' average 12-month target is $94.69 (+11% vs. $85.41). Targets range from $71.00 to $113.00. 53% rate it a buy.
SOLV earnings
Next report: November 5, 2026. Solventum has beaten EPS estimates 8 quarters in a row. Last quarter's revenue was $2.2B (+2% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 5, 2026 | $1.91 | $2.55 | +33.8% |
| May 5, 2026 | $1.35 | $1.48 | +9.3% |
| Feb 26, 2026 | $1.50 | $1.57 | +5.0% |
| Nov 6, 2025 | $1.43 | $1.50 | +4.7% |
| Aug 7, 2025 | $1.45 | $1.69 | +16.3% |
| May 8, 2025 | $1.22 | $1.34 | +9.7% |
| Feb 27, 2025 | $1.31 | $1.41 | +7.8% |
| Nov 7, 2024 | $1.39 | $1.64 | +17.7% |
Stocks like SOLV
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 VEEV Veeva Systems | +0.15% | +11% | $52.3B | 53.0x | Compare |
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
 JNJ Johnson & Johnson | -1.42% | +40% | $635.1B | 40.0x | Compare |
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 UNH UnitedHealth | -1.62% | +19% | $375.3B | 26.9x | Compare |
 MRK Merck & | -1.34% | +72% | $358.4B | 117.2x | Compare |
 TMO Thermo Fisher Scientific | -0.40% | +18% | $249.1B | 35.5x | Compare |
 AMGN Amgen | -1.79% | +54% | $237.5B | 27.3x | Compare |
SOLV news
- SOLV Wins FDA Clearance to Combine Restrata Matrix With V.A.C.Therapy · Oct 23, 2026
- Mexico Prefabricated Crown and Bridge Materials Market Outlook to 2036: Permanent Crowns and Bridges Revenue, Volume and Pricing · Oct 22, 2026
- Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026 · Oct 15, 2026
- Can Solventum (SOLV) Keep the Earnings Surprise Streak Alive? · Oct 8, 2026
- 2 Profitable Stocks for Long-Term Investors and 1 We Question · Sep 29, 2026
SOLV stock FAQ
What is SOLV's market cap?
Solventum's market capitalization is $14.54 billion as of October 23, 2026, ranking 453rd in the S&P 500.
What is SOLV's P/E ratio?
SOLV trades at a trailing price-to-earnings ratio of 10.5x and a forward P/E of 11.8x. Its median P/E over the period we track is 9.6x.
Does SOLV pay a dividend?
No. Solventum does not currently pay a regular cash dividend.
How much has SOLV stock returned?
Including reinvested dividends, SOLV returned +18.2% over one year through October 23, 2026.
What is the SOLV price target?
13 analysts cover SOLV with an average 12-month price target of $94.69, +11% from the current price. 53% of them rate it a buy.
When does SOLV report earnings?
Solventum is expected to report earnings on November 5, 2026. It has beaten EPS estimates 8 quarters in a row.
How many employees does Solventum have?
Solventum has about 20,584 full-time employees, or $403,712 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology